Skip to main content
Paul Richardson on Muck Rack

Paul Richardson

Verified
(He/Him)
Johannesburg
As seen in: Bloomberg News, LinkedIn, MSN, Bloomberg Businessweek, Bloomberg Green Daily, Bloomberg Markets Magazine, Nature, The Guardian, The Telegraph, Yahoo Canada, Yahoo News and
Covers:  I cover economy and government in sub-Saharan Africa
African economy and government coverage at Bloomberg News. All opinions my own. RT ≠ endorsement. Avatar by John Odoch-Ameny.

Get in touch with Paul

Contact Paul, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Paul Richardson’s Biography

Read Full Bio →

I manage Bloomberg News' economy and government team covering sub-Saharan Africa.
I've been based in Johannesburg, South Africa, since July 2018, following a seven-year stint in Nairobi, Kenya, where I was responsible for Bloomberg's East Africa coverage.
I've previously worked for Reuters (Johannesburg/London), Sunday Times (Johannesburg), ThisDay (Johannesburg/Lagos), I-Net Bridge, Business Day (Johannesburg).

Paul Richardson’s Journalist Portfolio

View article →

Articles

EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC

|
By Paul Richardson Verified, Muhamed Baljevic, Nisha Kapani
| ONCOLOGY journal Verified
The European Commission (EC) has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for the first-line treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC), according to a news release from Laboratoires Pierre Fabre.1 The decision designates this regimen as the first and only BRAF-targeted therapy authorized in the EU for patients with previously untreated disease.
Open in Who Shared View Duplicates (2) Issue with article?

Góc nhỏ kỳ diệu của Tây Ban Nha mà du khách chưa tìm thấy

|
By Paul Richardson Verified
| bbw.vn
Khám phá nhiều hơn với tài khoản Đăng nhập để lưu trữ và dễ dàng truy cập những bài viết bạn yêu thích trên Bloomberg Businessweek Việt Nam. Khám phá nhiều hơn với tài khoản Premium Góc nhỏ kỳ diệu của Tây Ban Nha mà du khách chưa tìm thấy BBWV - Những kho tàng văn hóa được cất giấu kỹ lưỡng tại vùng đất nằm sâu trong nội địa Extremadura, Tây Ban Nha.
Open in Who Shared Issue with article?

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial

|
By Omar Nadeem, Sarah Nikiforow, Elizabeth O’Donnell, Robert A. Redd, Adam S. Sperling, Yuxin Liu, Frances Arters, Colin A. O’Donnell, Marjorie Marto, Amy E. Bergeron, Kristin McHugh Verified, Abigail M. Caron, Elizabeth A. Grimm, Francesco Corrado, Kevin Panaro, Eric Smith Verified, Kenneth Anderson, Caron A Jacobson, Nikhil C. Munshi, Paul Richardson Verified, Deepu Madduri, Jordan M. Schecter, Craig Tendler, Lorenzo Trippa, Maria Mateos Verified, Jerome Ritz, Irene M. Ghobrial, Anna Bosch-Vilaseca, Kevin C. DeBraganca, Caleb McEntire, Brendan Kineavy, Emilie Swenson, Quentin Berry, Hope Wei, Emily Durlacher, Nayda Bidikian, Rocio Montes de Oca, Tamar Lengil, Denise De Wiest, Casey Gervais, Mark A. Wildgust
| Nature Verified
Abstract High-risk smoldering multiple myeloma (HR-SMM) carries an increased risk of progression to multiple myeloma, making it an ideal setting to test whether chimeric antigen receptor (CAR) T cell therapy can achieve curative outcomes. Here in this phase 2 study, patients with HR-SMM received ciltacabtagene autoleucel (cilta-cel) at 0.3–0.5 × 106 or >0.5 × 106 viable CAR+ T cells per kilogram without induction or bridging therapy. Patients with >40% marrow involvement were excluded.
Open in Who Shared Issue with article?
See all 356 licensed articles (701 Total)

Interview

See all →

What was your first job as a journalist?

Copy taster at Business Day, Johannesburg.

Have you ever used a typewriter?

Yes.

Who's your favorite fictional journalist?

William Boot